Professor Adamo’s research interests focus on the study of the transcriptional and epigenetic mechanisms dysregulated in metabolic disorders such as Insulin Resistance (IR) and Type II Diabetes Mellitus (T2DM). His team relies on the use of the innovative reprogramming technique to derive induced pluripotent stem cells (iPSCs) from fibroblasts obtained from large cohorts of patients and healthy donors. iPSCs can be differentiated to virtually all cell types of the human body and therefore constitute an unprecedented cellular platform to model disease progression. Professor Adamo’s team combines reprogramming, next generation sequencing (NGS), genome editing and cellular biology techniques to identify the transcriptional and epigenetic signatures prognostic of metabolic diseases and to develop in vitro screening assays aimed to isolate chemical compounds able to revert these pathological signatures.

Genomics